论文部分内容阅读
目的探讨莫西沙星序贯治疗社区获得性肺炎(CAP)的临床疗效。方法将108例CAP患者随机分为序贯组56例和对照组52例。序贯组给予莫西沙星静脉滴注3-5天,待病情稳定后予莫西沙星片剂口服;对照组予莫西沙星连续静脉滴注。1O天后比较两组的临床有效率、细茵清除率、不良反应和治疗费用。结果序贯组临床有效率为85.71%,对照组为88.46%;两组细菌清除率分别为83.78%和88.24%,两组不良反发生率分别为为5.56%和7.69%。两组临床有效率、细菌清除率及不良反应均无明显差异(P>0.05);序贯组平均住院费用为2686±533元,对照组3763±592元,序贯组住院费用明显低于对照组(P<0.05),有统计学意义。结论:莫西沙星序贯治疗CAP与连续静脉滴注莫西沙星疗效相似,住院费用低,值得临床推广应用。
Objective To investigate the clinical efficacy of sequential treatment of community-acquired pneumonia (CAP) with moxifloxacin. Methods 108 patients with CAP were randomly divided into sequential group of 56 cases and control group of 52 cases. The sequential group was given moxifloxacin intravenously for 3-5 days until oral administration of moxifloxacin tablets when the condition was stable. The control group was given continuous intravenous infusion of moxifloxacin. 1O days after the two groups compared the clinical efficiency, clearance rate, adverse reactions and treatment costs. Results The clinical effective rate was 85.71% in the sequential group and 88.46% in the control group. The bacterial clearance rates in the two groups were 83.78% and 88.24%, respectively. The adverse reaction rates in the two groups were 5.56% and 7.69%, respectively. There was no significant difference in clinical efficacy, bacterial clearance and adverse reactions between the two groups (P> 0.05). The average hospitalization cost was 2686 ± 533 yuan in the sequential group and 3763 ± 592 yuan in the control group. The hospitalization cost of the sequential group was significantly lower than that of the control group Group (P <0.05), with statistical significance. Conclusion: Sequential treatment of moxifloxacin with continuous intravenous infusion of moxifloxacin has similar efficacy and low hospitalization cost, which deserves clinical application.